الفهرس 
Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 191 |  |  |
| | | from | 191 | | |
Abstract
T
he aim of present study is evaluated lincRNA-p21, miRNA- 34a, and the tumor suppressor p53 (TP53) gene expression as molecular diagnostic and prognostic factors for B- chronic lymphocytic leukemia and correlate their expressions with different clinic-pathological parameters including phenotypes, hematological data and disease outcome. Also correlate lincRNA-p21 and miRNA-34a expression patterns with prognosis and prognostic markers to outline their possible role in CLL outcome. A total of 50 patients newly diagnosed CLL were selected to participate in the study and 25 healthy subject as a control group.
linc-RNA-p21 and p53 expression were significantly up regulated in B-CLL patients compared to healthy control, while miRNA-34a were significantly down regulated in B-CLL patients compared healthy control.
Plasma Linc-RNAp21, miRNA-34a and P53showed a statistically high significant correlation with other parameters (Rai-staging, Binet-staging, cytogenetics). However, there was no significant correlation with parameters (age andgender).
In addition, we conduct ROC analysis to detect the potential application of Lnc-p21 and miRNA-34a in the prognosis of CLL, from the analysis of our results, only Linc-p21 and TP53 gene expression could be used as prognostic biomarkers.
Our result showed that the Linc-p21 expression obtained an area under the curve (AUC) was19 with 88 % confidence interval and specificity 80%, in contrast to 0.13 shown in miR-34a expression with specificity 92%. On the other hand, TP53 expression obtained an area under the curve (AUC) was 2 with sensitivity (76%) and 84% specificity.The AUC, sensitivity and specificity was significant P< 0.05, so Linc-p21, miR-34a and TP53 in B-CLL patients could be used as diagnostic biomarkers.
ROC curve analysis of LincRNA-p21 showed the best sensitivity and specificity than miRNA34a in differentiation between CLL patients and healthy patients.